Rapamycin review: from immunosuppressant to reproducible geroprotector
This abstract reviews rapamycin, an mTOR inhibitor, from immunosuppressant to the most reproducible pharmacological geroprotector in geroscience, covering model-organism findings, human trials for diseases of aging, and side-effects that may limit clinical translation. [1]
Automatic summary · not editorially reviewed
The key findings
Rapamycin is described as an mTOR protein kinase inhibitor that evolved from an immunosuppressant to the most reproducible pharmacological geroprotector in geroscience. [1]
Model-organism findings revealed potent benefits of rapamycin for longevity, for multiple organ systems and on the hallmarks of aging. [1]
The authors discuss side-effects that may limit translation to the clinic and conclude rapamycin may yet extend healthspan and lifespan, with the jury still out. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Model organisms and humans with diseases of aging, as described in the abstract.
- Summary based on
- Study abstract
- Original publication
- May 13, 2026
Rapamycin's path from immunosuppressant to geroprotector
The abstract describes rapamycin as an inhibitor of the mTOR protein kinase and traces its evolution from an immunosuppressant to what the authors call the most reproducible pharmacological geroprotector in geroscience. It frames this against calorie restriction, identified almost a century ago as a robust intervention for extending lifespan and healthspan. The authors note the field is evolving rapidly, with basic science studies, clinical trials and off-label use of mTOR inhibitors by the general public expanding quickly.
Supporting source [1]
Model-organism benefits and human trials reviewed
The review covers findings in model organisms that revealed potent benefits of rapamycin not only for longevity but also for the function of multiple organ systems and on the hallmarks of aging. It also reviews completed and ongoing clinical trials of rapamycin and analogs for diseases of aging in humans. The abstract does not report specific effect sizes, trial results or participant numbers.
Supporting source [1]
Side-effects and open question of clinical translation
The authors discuss challenges and side-effects of rapamycin that may limit its translation from the laboratory to the clinic. They state that the jury is still out and conclude that rapamycin, or molecules that similarly inhibit mTOR, may yet realize the century-old dream of extending healthspan and lifespan with a small molecule. This is a stated possibility, not a demonstrated human outcome.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. No specific trial results, effect sizes, participant numbers or follow-up are reported here, and the lifespan and healthspan benefits described come from model organisms, not demonstrated human outcomes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Lamming DW. · europepmc.org · May 13, 2026